http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Seung Woon Paik ) (검색결과 359 건)
- 무료
- 기관 내 무료
- 유료
-
( Sang Hoon Ahn ),( Won Hyeok Choe ),( Yoon Jun Kim ),( Jeong Heo ),( Dorota Latarska-smuga ),( Jiho Kang ),( Seung Woon Paik ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Chronic Hepatitis C Virus (HCV) infection increases the risk for progressive liver disease, hepatocellular carcinoma and negatively impacts the patient’s quality of life. HCV treatment is evolving with direct acting antivirals but IFN based therapy has been the standard of care for many years and remains available in some countries. The MOSAIC study aims to characterize patients with chronic HCV infection and assess the impact of IFN-containing treatment on health-related quality of life, work related productivity and health care utilization. Methods: MOSAIC is an international prospective multicenter observational study that has been conducted in 20 countries. Consecutive patients with chronic HCV infection were enrolled and those who initiated an IFN based regimen were prospectively followed for 48 weeks. We report results from the Korean cohort Results: 100 patients were enrolled: 86 were treatment naïve and 14 were treatment experienced. 33 patients initiated an IFN based regimen: 6 patients started IFN + RBV, 26 patients started Peg-IFN + RBV, none started Peg-IFN + RBV + DAA and 1 patient received other treatment. Among the treated cohort, demographic and disease characteristics were the following: the mean age was 54.5 years; 14 patients were male. 14 had minimal or no fibrosis, 2 portal fibrosis, 3 bridging fibrosis and 6 patients suffered from cirrhosis. HCV Genotype distribution was as follows: genotype 1: 11; genotype 2: 19 and genotype 3: 3. Table 1 describes the results at baseline and changes over 4, 12 and 48 weeks and end-of-treatment (EOT) for the quality of life and work productivity outcome measures (EQ-5D-5L, HCV-PRO and WPAI). Conclusions: Results from the Korean cohort of the MOSAIC study show a moderate trend for deterioration of health-related quality of life and work productivity associated with IFN based treatment for patients with chronic HCV infection during treatment period. Acknowledgements: The design, study conduct, analysis, and financial support of MOSAIC study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the content of the abstract. All authors had access to all relevant data and participated in writing, review, and approval of this abstract. Medical writing support was provided by Olivier Van de Steen of Medeor-consulting, funded by AbbVie. Disclosures: Sang Hoon Ahn: served as an advisor and lecturer for Bristol-Myers Squibb, Gilead Sciences, F.Hoffmann-La Roche, Merck, AbbVie, and has received unrestricted grants from Bristol-Myers Squibb, Gilead Sciences, and F. Hoffmann-La Roche for investigator- initiated trials Won Hyeok Choe: Nothing to disclosure Yoon Jun Kim: Nothing to disclosure Jeong Heo: received a grant from GSK; Research support from BMS, and Roche; Advisor for Abbvie, BMS, Gilead Sciences, Pharma Essentia, SillaJen, and Johnson & Johnson. Dorota Latarska-Smuga, Jiho Kang: are employees of AbbVie, Inc. and may hold stock or stock options. Seung Woon Paik: received grant and research support from AbbVie, BMS, Gilead, GSK, Merck, Novartis, and Roche
-
( Seung Woon Paik ),( Chi-jen Chu ),( Yan Luo ),( Kwang-hyub Han ),( Jia-horng Kao ),( Jeong Heo ),( Cheng-yuan Peng ),( Yoon Jun Kim ),( Ting-tsung Chang ),( Young-suk Lim ),( Ming Lung Yu ),( Linda 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Background: Chronic hepatitis C virus (HCV) infection is associated with development of complications including hepatocellular carcinoma, liver failure and cirrhosis. Patients with cirrhosis are historically more difficult to cure. In southeastern Asia, the most prevalent HCV genotype (GT) is GT1b. In western populations, the 3 direct-acting antiviral (3-DAA) regimen of ombitasvir (OBV), ritonavir-boosted paritaprevir (PTV/r; identified by AbbVie and Enanta) and dasabuvir (DSV) ± ribavirin (RBV) demonstrated sustained virologic response (SVR) at post-treatment week 12 (SVR12) rates of 99% in patients with GT1b infection and compensated cirrhosis regardless of prior treatment experience. The regimen, however, has not been investigated in southeastern Asian populations. The ONYX-II study is evaluating the efficacy and safety of this regimen in Asian patients with HCV GT1b infection and compensated cirrhosis. Methods: Treatment-naive and interferon-based therapy-experienced patients with HCV GT1b-infection and compensated cirrhosis were enrolled in South Korea, Taiwan, and China, and received 12 weeks of OBV/PTV/r (25 mg/150 mg/100 mg once daily) and DSV (250 mg twice daily) with RBV (weight-based). Patients will be followed for 48 weeks after the last dose of study drugs. The primary objectives are to compare the SVR12 rate to the known SVR rate of telaprevir + peg-interferon (IFN) + RBV therapy, and to assess the safety of OBV/PTV/r + DSV + RBV. Results: Twenty-one and 20 subjects were enrolled in South Korea and Taiwan, respectively. Of South Korean patients, 52% were male and 71% were treatment-experienced; of Taiwanese patients, 45% were male and 65% were treatment-experienced. Safety data and SVR at post-treatment week 4 (SVR4) will be available for presentation. Conclusions: The ONYX-II study evaluates the 3-DAA regimen of OBV/PTV/r + DSV with RBV for Asian patients with compensated cirrhosis and HCV GT1b infection. Resultant data may provide evidence for treatment guidelines for HCV GT1b in this population.
-
-
만성 B형간염환자의 재발 방지 및 삶의 질 향상을 위한 시스템 다이내믹스 모델 개발
백승운 ( Seung Woon Paik ),최은옥 ( Eun Ok Choi ),김금순 ( Keum Soon Kim ),이명선 ( Myung Sun Yi ),곽상만 ( Sang Man Kwak ) 한국시스템다이내믹스학회 2006 한국시스템다이내믹스 연구 Vol.7 No.2
A conceptual system dynamics model is developed to represent the dynamic mechanism between the number of hepatitis B virus and the defense system of the body. The simulation results shows that the model behaves within the reasonable ranges. The developed conceptual model is a first attempt to quantify the dynamic mechanisms of the hepatitis B virus, where only feedback structures are considered without bio-organism data. The next step would be to incorporate the model with bio-organism theory and to carry out case studies to identify personal characteristics. Since the current model is a conceptual model where quantitative results are not based on the sound background, the usage is limited only within the qualitative basis. It could be a effective educational tool for the patients. It also shows what-to-do lists in order to be used for forecast purposes. * This study was funded by "the Korea Research Foundation Grant" (KRF-2004-042-E00147) in 2004.
-
( Namyoung Paik ),( Dong Hyun Sinn ),( Jung Hee Kim ),( Wonseok Kang ),( Geum-youn Gwak ),( Yong-han Paik ),( Moon Seok Choi ),( Joon Hyeok Lee ),( Kwang Cheol Koh ),( Seung Woon Paik ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: The prognosis of chronic hepatitis B virus (HBV) infected patientsshowing low level viremia (HBV DNA < 2,000 IU/mL) are generallyexcellent, yet, those with cirrhosis are still at risk for developing hepatocellularcarcinoma (HCC). Liver biopsy is the gold standard to differentiatecirrhosis in this population, yet, due to its invasiveness, manyhad to rely on noninvasive liver fibrosis predictors. We tested whethersimple noninvasive liver fibrosis predictors, the AST to platelet ratioindex (APRI) and the Fibrosis-4 (FIB-4), can effectively risk-stratify HCCrisk in patients with low level viremia.Methods: A retrospective cohort of 1,380 CHB patients with low levelviremia (HBV DNA < 2,000 IU/mL) was assessed for the developmentof HCC. Cirrhosis was defined clinically by cirrhotic configuration,varix, thrombocytopenia with splenomegaly. Based on APRI and FIB-4score, patients were divided into two groups based on known cutoff(0.5 for APRI and 1.45 for FIB-4), which has shown high negativepredictive value for advanced fibrosis.Results: During a median 5.7 years (range: 1.0-9.2 years) of follow-up,HCC developed in 65 patients. The HCC incidence rate was higherfor cirrhotic patients (40/237 patients, 16.7% at 5-years), but wasnot null for non-cirrhotic patients (25/1,143 patients, 1.9% at 5-years,p < 0.001). The AUROCs for the HCC development at 3/5 yearswas 0.78/0.73, 0.79/0.78, and 0.79/0.76 for cirrhosis, APRI and FIB-4,among overall cohort, respectively, and was 0.73/0.83 and 0.83/0.89for APRI and FIB-4, among non-cirrhotic patients. When stratifiedby APRI and FIB-4, the 5-year cumulative HCC incidence rate was13.7%, 2.8% and 1.4% for both high, any high, and both lowAPRI and FIB-4, among overall cohort (p < 0.001), and was 11.5%,2.4% and 0.2% for both high, any high, and both low APRI andFIB-4, among non-cirrhotic patients (p < 0.001), respectively.Conclusions: The combined use of APRI and FIB-4 can effectively riskstratify individuals risk for HCC, and can be useful in clinical practicefor the HCC prediction among patients with low level viremia, includingthose without clinical evidence of cirrhosis.
-
-
백승운 ( Seung Woon Paik ) 대한소화기학회 2008 대한소화기학회지 Vol.51 No.6
Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatic fibrosis worldwide. Up to 85% of individuals infected with HCV develop chronic infection, which can progress to cirrhosis and hepatocellular carcinoma. The primary goal in the treatment of HCV infection is to reduce the mortality by preventing liver-related deaths associated with the development of hepatocellular carcinoma and decompensated cirrhosis. Pegylated interferons together with ribavirin are currently the standard of care for patients with chronic hepatitis. Here, I discuss the goals of treatment, indication and treatment of chronic hepatitis C. (Korean J Gastroenterol 2008;51: 368-371)
-
-
-
우리나라 간암 환자에서의 Cytochrome p450 2E1유전자의 다형성에 관한 연구
백승운,이효석,김정룡,윤정환,장유현,황유진 대한소화기학회 1998 대한소화기학회지 Vol.30 No.4
Background/Airns: Cytochrome P450 2E1(CYP2EI) is the only enzyme that rnetabolizes very low doses of N-nitrosodimethylamine(NDMA) and is characterized by its ethanol inducibility. Recently, it has been shown in an animal-experimental study that NDMAinduced hepatocarcinogenes was facilitated by chronic alcohol ingestion. CYP2E1 expression in human beings was reported to be about 10 times higher in genotype c2/c2 than in genotype c1/c1. Bacause CYP2El gene expression is the highest in the liver, we hypothesized that the polymorphism of CYP2E1 may affect the risk of hepatocellular carcinoma(HCC), especially in patients with chronic alcohol consumption. Methods: We enrolled 46 HCC patients and 32 age-sex-matcied healthy controls without liver disease or cancer in any other organ. The genotypes in the 5-flanking region of CYP2E1 gene were determined by restriction fragment length polymorphisms using two endonucleases: PstI and RsaI. Results: The frequencies of genotype A(c1/c1), B(c1/c2) and C(c2/c2) were 56.5%, 39.1%, 4.4% in HCC patients, and 62.5%, 28.1%, 4.4% in controls, regiectively. The frequency of allele c2 was 23.9% in HCC patients and 23.4% in control, re.;pectively. The difference in the frequencies of both CYP2E1 genotyps and alleles was not statistically significant between the HCC patients and controls. The HCC patients with a history of ckonic alcohol ingestion were more like]y to carry genotype B and C than in patients without such history, even though the differences are not statistically significant(p=0.077). Conclusions: Although polymorphisms of CYP2E1 gene is not a major genetic risk factor for the development of HCC, it might increase the risk of HCC in patients with chronic HBV or HCV infection and chronic alcohol consumption. Further study to test this bypothesis on a large number of patients and on patients of different ethnic groups is warranted.
ScienceON연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
